Seeking Alpha1d
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
Hims & Hers' strong Q3 results and 77% y/y revenue growth demonstrate its robust business, justifying a continued strong ...
Hims & Hers price target raised to $21 from $18 at Piper Sandler
Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $21 from $18 and keeps a Neutral rating on ...
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Becker's Hospital Review7h
Hims & Hers to sell generic weight loss drug in 2025
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Jonna Kim’s Buy Recommendation: Hims & Hers Health’s Robust Growth Trajectory and Market Potential
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Hims & Hers to launch a generic for Novo’s older GLP-1
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Hims & Hers will start selling a generic weight loss drug
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...
Stocktwits on MSN15h
Hims & Hers Soars Pre-Market After Analysts Boost Price Targets On Strong Q3 Performance
Hims & Hers Health Inc. ($HIMS) rallied nearly 9% in pre-market trading on Tuesday, following the company’s third-quarter ...